You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Medtronic
Dow
Mallinckrodt
Express Scripts

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Marcaine Hydrochloride W/ Epinephrine patents expire, and when can generic versions of Marcaine Hydrochloride W/ Epinephrine launch?

Marcaine Hydrochloride W/ Epinephrine is a drug marketed by Hospira and is included in one NDA.

The generic ingredient in MARCAINE HYDROCHLORIDE W/ EPINEPHRINE is bupivacaine hydrochloride; epinephrine bitartrate. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride; epinephrine bitartrate profile page.

Summary for MARCAINE HYDROCHLORIDE W/ EPINEPHRINE
Drug patent expirations by year for MARCAINE HYDROCHLORIDE W/ EPINEPHRINE
Recent Clinical Trials for MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Louisiana State University Health Sciences Center in New OrleansN/A
Our Lady of the Lake HospitalN/A
University of Wisconsin, MadisonPhase 4

See all MARCAINE HYDROCHLORIDE W/ EPINEPHRINE clinical trials

Pharmacology for MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

US Patents and Regulatory Information for MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira MARCAINE HYDROCHLORIDE W/ EPINEPHRINE bupivacaine hydrochloride; epinephrine bitartrate INJECTABLE;INJECTION 016964-004 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Hospira MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE bupivacaine hydrochloride; epinephrine bitartrate INJECTABLE;INJECTION 016964-007 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Hospira MARCAINE HYDROCHLORIDE W/ EPINEPHRINE bupivacaine hydrochloride; epinephrine bitartrate INJECTABLE;INJECTION 016964-008 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Hospira MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE bupivacaine hydrochloride; epinephrine bitartrate INJECTABLE;INJECTION 016964-013 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Hospira MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE bupivacaine hydrochloride; epinephrine bitartrate INJECTABLE;INJECTION 016964-010 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Express Scripts
McKinsey
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.